Rapid Micro Biosystems, INC

Rapid Micro Biosystems stockholders elected a Class II director and ratified the appointment of its independent auditor at the 2026 Annual Meeting.

Rapid Micro Biosystems, Inc. announced the closing of an underwritten offering of common stock and warrants, raising approximately $9 million.

Rapid Micro Biosystems reported an 11% increase in first-quarter 2026 revenue to $8.0 million, driven by product and recurring revenue growth, though net loss expanded to $14.3 million.

Rapid Micro Biosystems announced Chief Operating Officer John Wilson's departure, with CEO Robert Spignesi taking on principal operating officer duties.

Rapid Micro Biosystems announced record fourth quarter and full year 2025 financial results, alongside significant multi-system orders from Amgen and Samsung Biologics, and provided 2026 guidance.

Rapid Micro Biosystems, Inc. announced preliminary unaudited record revenue for the fourth quarter and full year 2025, exceeding raised guidance.

Rapid Micro Biosystems, Inc. reported an 11.1% increase in total revenue for the first quarter of 2026, reaching $8.0 million, despite a wider net loss.

Rapid Micro Biosystems reports improved nine-month financial performance with reduced net losses and increased revenue, driven by recurring sales and a new debt facility.

Rapid Micro Biosystems reports increased revenue and improved gross margins in Q2 2025, securing a new $45 million debt facility to bolster liquidity despite continued net losses.

Rapid Micro Biosystems reports a 28.4% increase in revenue for Q1 2025, driven by service revenue growth and cost reduction initiatives, while still operating at a net loss.

Rapid Micro Biosystems announced its Q3 2024 results, highlighting revenue growth and the implementation of an operational efficiency program aimed at achieving positive cash flow by the end of 2027.

Rapid Micro Biosystems announced its second quarter 2024 results, highlighting revenue growth and the implementation of a cost-cutting program aimed at achieving positive cash flow by the end of 2027.

Rapid Micro Biosystems reports increased revenue and positive gross margins for 2025, driven by system placements and strategic partnerships, despite continued net losses.

Rapid Micro Biosystems' 2024 10-K filing highlights a year of financial losses but also strategic advancements, including a new distribution agreement and progress towards profitability.

Rapid Micro Biosystems' 10-K filing outlines the company's capital stock structure, registration rights, anti-takeover measures, and compliance with SEC regulations.

Richard S Kollender, a Director of Rapid Micro Biosystems, Inc., reported multiple transactions in common stock on July 24, 2026.

Robert G. Spignesi Jr., PRESIDENT AND CEO and a Director of Rapid Micro Biosystems, Inc., reported multiple transactions in common stock on July 22, 2026.

Director Inese Lowenstein acquired 12,787 shares of Rapid Micro Biosystems, Inc. as part of a registered direct offering.

Director Melinda Litherland Pei acquired 12,787 shares of Rapid Micro Biosystems in a registered direct offering.

Director Kirk Malloy acquired 12,787 shares and accompanying warrants in a registered direct offering by Rapid Micro Biosystems.

Rapid Micro Biosystems CFO Sean Wirtjes acquired 12,787 shares and accompanying warrants in a registered direct offering.

Rapid Micro Biosystems announces its 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, to elect a director and ratify auditor appointment, with virtual attendance options.

Rapid Micro Biosystems has filed a definitive proxy statement with the SEC.

Rapid Micro Biosystems will hold its 2025 Annual Meeting of Stockholders virtually on May 22, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Rapid Micro Biosystems, Inc. has filed a definitive proxy statement with the SEC.

Rapid Micro Biosystems will conduct its 2024 Annual Meeting of Stockholders virtually on May 23, 2024, and is seeking stockholder approval for key proposals, including the election of directors and an amendment to allow officer exculpation.

Rapid Micro Biosystems CEO Robert G. Spignesi Jr. filed a Schedule 13D, disclosing a 6.3% beneficial ownership in the company's Class A Common Stock.

Longitude Capital Partners II, LLC and associated entities reported a beneficial ownership of 8.6% in Rapid Micro Biosystems, Inc. as of March 31, 2026.

Endeavour Medtech Growth II LP and affiliates reported a 5.7% beneficial ownership stake in Rapid Micro Biosystems, Inc. as of December 31, 2025.